デフォルト表紙
市場調査レポート
商品コード
1379996

関節リウマチ治療薬の世界市場 - 世界の産業規模、シェア、動向、機会、2018年~2028年、予測、分子タイプ別、薬剤クラス別、流通チャネル別、地域別、競合

Rheumatoid Arthritis Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028 Segmented By Type of Molecule, By Drug Class, By Distribution Channel, By Region, Competition

出版日: | 発行: TechSci Research | ページ情報: 英文 181 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

関節リウマチ治療薬の世界市場 - 世界の産業規模、シェア、動向、機会、2018年~2028年、予測、分子タイプ別、薬剤クラス別、流通チャネル別、地域別、競合
出版日: 2023年10月03日
発行: TechSci Research
ページ情報: 英文 181 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の関節リウマチ治療薬市場は、2022年に592億米ドルと評価され、2028年までのCAGRは5.58%で、予測期間中に目覚ましい成長を予測しています。

世界の関節リウマチ(RA)治療薬市場は、医薬品業界の中でもダイナミックで急速に発展している分野です。この市場の特徴は、RA患者のニーズに対応することを目的とした継続的な研究開発努力によって、革新的な治療薬が絶えず流入していることです。

関節リウマチは、主に関節を侵し、痛み、腫れ、こわばりを引き起こす自己免疫疾患です。未治療のまま放置すると、関節の変形や障害を引き起こすこともあります。RAの世界の有病率は人口の約1%と推定され、男性よりも女性の方が罹患率が高いです。世界人口の高齢化に伴い、RAの罹患率は上昇すると予想されています。

主な市場促進要因

市場概要
予測期間 2024年~2028年
2022年の市場規模 592億米ドル
2028年の市場規模 810億5,000万米ドル
CAGR 2023年~2028年 5.58%
急成長セグメント 店頭販売
最大市場 北米

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の関節リウマチ治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 分子タイプ別(医薬品、バイオ医薬品)
    • 薬剤クラス別(非ステロイド性抗炎症薬(NSAIDs)、疾患修飾性抗リウマチ薬(DMARDs)、副腎皮質ステロイド薬、鎮痛薬、その他)
    • 流通チャネル別(処方薬、OTC薬)
    • 地域別
    • 企業別(2022年)
  • 市場マップ

第6章 北米の関節リウマチ治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 分子タイプ別
    • 薬剤クラス別
    • 流通チャネル別
    • 国別
  • 北米:国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の関節リウマチ治療薬市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 分子タイプ別
    • 薬剤クラス別
    • 流通チャネル別
  • 欧州:国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋の関節リウマチ治療薬市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 分子タイプ別
    • 薬剤クラス別
    • 流通チャネル別
  • アジア太平洋:国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の関節リウマチ治療薬市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 分子タイプ別
    • 薬剤クラス別
    • 流通チャネル別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの関節リウマチ治療薬市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 分子タイプ別
    • 薬剤クラス別
    • 流通チャネル別
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因と課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 関節リウマチ治療薬の世界市場SWOT分析

第14章 競合情勢

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG

第15章 戦略的提言

第16章 調査会社・免責事項

目次
Product Code: 17264

Global Rheumatoid Arthritis Drugs Market has valued at USD 59.20 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.58% through 2028. The Global Rheumatoid Arthritis (RA) Drugs market is a dynamic and rapidly evolving sector within the pharmaceutical industry. This market is characterized by a constant influx of innovative therapies, driven by ongoing research and development efforts aimed at addressing the needs of RA patients.

Rheumatoid arthritis is an autoimmune disease that primarily affects the joints, causing pain, swelling, and stiffness. It can also lead to joint deformities and disability if left untreated. The global prevalence of RA is estimated to be around 1% of the population, with women being more commonly affected than men. As the global population ages, the incidence of RA is expected to rise.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 59.20 Billion
Market Size 2028USD 81.05 Billion
CAGR 2023-20285.58%
Fastest Growing SegmentOver-the-counter
Largest MarketNorth America

Advancements in Research and Development

Advancements in Research and Development (R&D) stand as a pivotal and potent market driver for the Global Rheumatoid Arthritis (RA) Drugs Market. At the heart of R&D lies the continuous quest for innovative drug development. Pharmaceutical companies, driven by the pressing need to address the complexities of rheumatoid arthritis, are investing heavily in research. These investments are geared towards creating drugs that not only alleviate symptoms but also tackle the underlying causes of the disease. Such drugs offer a comprehensive solution to RA patients, promising a better quality of life and potentially halting the progression of the disease. Recent advancements in biotechnology and molecular biology have paved the way for precision medicine in the treatment of rheumatoid arthritis. Researchers are now able to understand the disease at a molecular level, identifying specific targets within the immune system responsible for inflammation and joint damage. This has led to the development of highly targeted therapies that can be tailored to individual patients based on their genetic and immune profiles. Precision medicine not only enhances treatment effectiveness but also minimizes side effects, making it an attractive option for both patients and healthcare providers.

R&D efforts have resulted in the emergence of biologics and targeted therapies as game-changers in the RA drugs market. Unlike traditional drugs, which provide a general suppression of the immune system, biologics specifically target molecules involved in the inflammatory process. This targeted approach not only improves efficacy but also reduces the risk of adverse events. The success stories of biologics like adalimumab and etanercept have reshaped the treatment landscape for rheumatoid arthritis, offering patients newfound hope for managing their condition. Alongside novel drug compounds, R&D is also focused on developing innovative drug delivery methods. This includes the exploration of oral, subcutaneous, and even wearable technologies that enhance patient compliance and convenience. By providing patients with more user-friendly and less invasive options, pharmaceutical companies can significantly expand their market reach and cater to a broader patient demographic.

Rising Prevalence of Rheumatoid Arthritis

The rising prevalence of Rheumatoid Arthritis (RA) is a significant and undeniable market driver for the Global Rheumatoid Arthritis Drugs market. One of the primary reasons behind the increasing prevalence of RA is the aging population. As individuals grow older, the risk of developing RA rises. This demographic trend is particularly notable in developed countries where life expectancy is increasing, contributing to a larger pool of potential RA patients.

Advances in medical technology have led to more accurate and timely diagnosis of RA. Early detection is vital for effective management of the disease, and improved diagnostic techniques have allowed healthcare professionals to identify RA cases that might have gone undetected in the past. As a result, more individuals are receiving a confirmed diagnosis, contributing to the growing prevalence of RA. Modern lifestyles, characterized by sedentary behavior, unhealthy diets, and increased stress levels, are believed to be associated with an elevated risk of autoimmune diseases like RA. These factors, which are prevalent in many parts of the world, contribute to the increasing incidence of RA among the population.

Certain environmental factors, such as exposure to pollution and toxins, have been linked to an increased risk of developing RA. As industrialization continues to expand globally, more people are exposed to these environmental triggers, further driving the prevalence of the disease. The global rise in obesity rates is another contributing factor. Obesity is associated with a higher risk of RA, as excess body fat can lead to chronic inflammation, a key feature of the disease. The obesity epidemic has created a larger population at risk for RA.

Expanding Biologics Market

The expanding biologics market is a pivotal market driver for the Global Rheumatoid Arthritis (RA) Drugs market, transforming the landscape of RA treatment. Biologics represent a revolutionary approach to treating RA by specifically targeting molecules involved in the inflammatory process. Unlike traditional disease-modifying antirheumatic drugs (DMARDs), which provide broad immunosuppression, biologics offer precision medicine. This precise targeting not only enhances treatment efficacy but also minimizes the risk of adverse side effects, making biologics an attractive choice for both patients and healthcare providers. Biologics have demonstrated superior efficacy in RA management, often achieving better control of symptoms and joint damage than conventional therapies. Moreover, some biologics have shown the potential for disease modification, which means they can slow or even halt the progression of RA. This remarkable capability has elevated biologics to the forefront of RA treatment.

The biologics market for RA offers a wide array of products, each with distinct mechanisms of action. This diversity allows healthcare providers to tailor treatment plans to individual patients, optimizing outcomes. Some biologics target tumor necrosis factor-alpha (TNF-α), while others focus on interleukins (ILs) or B-cells. This versatility ensures that patients receive personalized and effective therapies. Biologics have been instrumental in improving the quality of life for RA patients. By effectively controlling inflammation and reducing pain, stiffness, and joint damage, these drugs enable patients to lead more active and fulfilling lives. This, in turn, has boosted patient satisfaction and compliance, driving the demand for biologics.

Government Initiatives and Healthcare Policies

Government initiatives and healthcare policies are significant market drivers for the Global Rheumatoid Arthritis (RA) Drugs market. These drivers are instrumental in shaping the landscape of RA treatment and pharmaceutical market dynamics. Government initiatives often aim to enhance patient access to essential medications, including RA drugs. By subsidizing the cost of these medications or implementing reimbursement schemes, governments reduce the financial burden on patients, making treatment more affordable and accessible. This encourages a broader patient demographic to seek treatment and boosts the demand for RA drugs. Many healthcare policies emphasize early diagnosis and intervention for RA. These policies promote regular screening and education about the disease, enabling healthcare providers to identify cases in their early stages. Early diagnosis allows for timely initiation of treatment, which can lead to better outcomes and reduced long-term healthcare costs.

Governments allocate funding for medical research, including studies focused on improving RA treatments. This funding supports clinical trials, drug development, and the exploration of innovative therapies. As a result, pharmaceutical companies benefit from partnerships with government-funded research institutions, expediting drug discovery and development. Government agencies, such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe, play a pivotal role in the approval and regulation of RA drugs. Favorable regulatory processes and expedited approvals for breakthrough therapies incentivize pharmaceutical companies to invest in RA drug development.

Key Market Challenges

High Cost of Biologic Therapies

Developing biologic drugs, which are at the forefront of RA treatment, involves substantial research and development expenditures. The intricate processes, complex biotechnology, and stringent regulatory requirements contribute to high R&D costs.

Manufacturing biologics is a complex and expensive process due to the need for living cell cultures, stringent quality control, and specialized facilities. These factors increase production costs, which are passed on to patients and healthcare systems. Many biologic drugs enjoy patent protection, granting pharmaceutical companies a period of exclusivity during which they can charge premium prices. While this incentivizes innovation, it also results in high costs for patients and healthcare payers.

The high cost of biologic therapies can limit patient access, particularly in regions with limited healthcare budgets. Patients may face financial barriers to treatment, leading to delayed or inadequate care. This, in turn, can slow down the overall market growth for RA drugs, as a substantial portion of the patient population may not have access to these advanced treatments.

Complex Regulatory Environment

Regulatory agencies require comprehensive safety and efficacy data for drug approval, especially for biologics. Meeting these stringent standards necessitates extensive clinical trials and robust data, which can be time-consuming and costly. RA drugs are marketed globally, and each country has its regulatory framework. Navigating multiple regulatory pathways and satisfying diverse requirements adds complexity to drug development and market entry.

The complex and time-consuming regulatory processes can delay the introduction of new RA drugs to the market. This delays access to innovative therapies for patients, potentially limiting market growth. Moreover, the resource-intensive nature of regulatory compliance can deter smaller pharmaceutical companies from entering the market, reducing competition and innovation.

Drug Resistance and Safety Concerns

Some RA patients may develop antibodies against biologic drugs over time, rendering these therapies less effective. This phenomenon can necessitate switching to alternative treatments, increasing healthcare costs. While biologics have shown significant benefits, they are not without risks. Adverse events, though relatively rare, can occur. Safety concerns can lead to increased monitoring, regulatory scrutiny, and even market withdrawals, impacting patient confidence.

Drug resistance and safety concerns can create uncertainties for both patients and healthcare providers. The need for continuous monitoring and potential therapy changes can increase the overall healthcare burden and dampen patient and provider enthusiasm for RA drugs. Additionally, safety concerns can lead to stricter regulatory oversight, potentially affecting market dynamics.

Key Market Trends

Biologic Therapies Dominance

Biologic drugs, which include TNF inhibitors, IL-6 inhibitors, and JAK inhibitors, have demonstrated superior efficacy in RA management. They specifically target molecules involved in the inflammatory process, providing precise control of the disease.

Biologics offer a lower risk of adverse side effects compared to traditional disease-modifying antirheumatic drugs (DMARDs), as they target specific pathways without suppressing the entire immune system. This has made them the preferred choice for many patients and healthcare providers. The global prevalence of RA is increasing, creating a growing patient pool in need of effective treatments. Biologics are at the forefront of meeting this demand, and pharmaceutical companies continue to invest in their development.

Biologic therapies are expected to maintain their dominance in the RA drugs market. As more biologics enter the market and gain regulatory approvals, patients are likely to benefit from a broader range of treatment options, leading to increased competition and innovation.

Shift Towards Personalized Medicine

Advances in medical research have identified biomarkers associated with RA. These biomarkers help predict disease severity and treatment response. With personalized medicine, treatment plans can be tailored to individual patients based on their biomarker profiles.

Genetic studies have revealed that RA has a strong genetic component. Understanding a patient's genetic predisposition can guide treatment decisions. For example, certain genetic markers may indicate a better response to specific biologics. Enhanced diagnostic techniques, including imaging and genetic testing, allow for more accurate and early diagnosis of RA. Early diagnosis facilitates timely intervention with personalized treatment strategies.

Personalized medicine is becoming increasingly relevant in the RA drugs market. Tailored treatments can lead to better outcomes and reduced healthcare costs. Pharmaceutical companies are investing in research to develop drugs that align with personalized treatment approaches.

Emergence of Biosimilars

Many biologic drugs used in RA treatment have reached or are approaching the end of their patent exclusivity. This has paved the way for the development and approval of biosimilars, which are highly similar to the original biologics but come at a lower cost.

Biosimilars offer a cost-effective alternative to brand-name biologics. They can reduce the financial burden on healthcare systems and make RA treatment more accessible to a broader patient population. Regulatory agencies have established rigorous guidelines for the approval of biosimilars, ensuring their safety and efficacy. This has fostered confidence among healthcare providers and patients in using biosimilars.

Biosimilars are gaining traction in the RA drugs market. Their affordability and effectiveness are driving their adoption. As more biosimilars enter the market and compete with established biologics, pricing pressures may lead to cost reductions across the board, benefiting patients and healthcare systems.

Segmental Insights

Type of Molecule Insights

Based on the category of Type of Molecule, the biopharmaceuticals segment emerged as the dominant player in the global market for Rheumatoid Arthritis Drugs in 2022. Biopharmaceuticals, which include biologics and biosimilars, have established themselves as the cornerstone of RA treatment. Biopharmaceuticals, particularly biologics, are designed to target specific molecules and pathways involved in the inflammatory process underlying RA. These drugs focus on key cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), or Janus kinase (JAK) pathways, which play pivotal roles in RA pathogenesis. By precisely targeting these molecules, biologics can effectively modulate the immune response, reduce inflammation, and halt disease progression. This targeted approach offers superior efficacy compared to traditional small molecule drugs that provide more generalized immunosuppression.

Biologics have consistently demonstrated higher efficacy in clinical trials and real-world settings when compared to traditional disease-modifying antirheumatic drugs (DMARDs). They often achieve better control of RA symptoms, such as joint pain, swelling, and stiffness. Additionally, biologics have the potential for disease modification, meaning they can slow or even halt the progression of RA, preserving joint function and preventing structural damage. This superior efficacy has made biopharmaceuticals the first choice for many RA patients and healthcare providers.

One significant advantage of biopharmaceuticals is their reduced risk of adverse side effects compared to small molecule drugs. Traditional DMARDs and nonsteroidal anti-inflammatory drugs (NSAIDs) often come with a higher risk of gastrointestinal issues, cardiovascular events, and liver toxicity. In contrast, biologics are generally better tolerated due to their targeted mechanism of action. This safety profile enhances patient compliance and satisfaction. These factors are expected to drive the growth of this segment.

Drug Class Insight

Based on the category of Drug Class, the disease-modifying antirheumatic drugs (DMARDs) segment emerged as the dominant player in the global market for Rheumatoid Arthritis Drugs in 2022. Disease-modifying antirheumatic drugs (DMARDs) are designed to address the root causes of RA rather than just alleviating symptoms. They work by modifying the immune system's abnormal response, reducing inflammation, and slowing down joint damage. This comprehensive approach to disease management sets DMARDs apart from other drug classes, making them an essential component of RA treatment. DMARDs have a well-established history of use in RA treatment, dating back to the introduction of traditional DMARDs like methotrexate and sulfasalazine. Their effectiveness in managing RA has been documented in numerous clinical trials and real-world studies. This track record of success has fostered trust among healthcare providers and patients, reinforcing the dominance of DMARDs.

DMARDs are often recommended as first-line therapy for RA, especially in newly diagnosed cases. They are considered the initial treatment choice due to their disease-modifying properties and relatively favorable safety profiles. Starting RA treatment with DMARDs is a widely accepted practice, ensuring their continued prominence in the market.

In many cases, DMARDs are used in combination with other drug classes, such as biologics or nonsteroidal anti-inflammatory drugs (NSAIDs). This combination therapy approach can enhance treatment outcomes by addressing different aspects of the disease. DMARDs serve as the foundational component of combination regimens, solidifying their role in RA management.

Distribution Channel Insights

The prescription segment is projected to experience rapid growth during the forecast period. Many RA drugs, especially biologics and disease-modifying antirheumatic drugs (DMARDs), are classified as prescription-only medications by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This means that they can only be legally dispensed to patients with a valid prescription from a licensed healthcare provider. The strict regulatory oversight and safety concerns associated with these drugs necessitate their prescription status. RA is a complex autoimmune disease that requires specialized knowledge and expertise to manage effectively. Healthcare professionals, including rheumatologists and primary care physicians, play a crucial role in diagnosing and determining the most appropriate treatment plan for RA patients. Prescription drugs are typically administered under the guidance of these experts to ensure safe and effective therapy. These factors collectively contribute to the growth of this segment.

Regional Insights

North America emerged as the dominant player in the global Rheumatoid Arthritis Drugs market in 2022, holding the largest market share in terms of value. North America has a relatively high prevalence of RA, particularly in the United States. This prevalence drives the demand for RA drugs, making it a significant market for pharmaceutical companies. North America boasts a highly advanced healthcare infrastructure with access to cutting-edge diagnostics and treatments. This infrastructure enables timely diagnosis and treatment of RA, contributing to the growth of the RA drugs market. The region is home to numerous pharmaceutical companies engaged in the research, development, and marketing of RA drugs. These companies benefit from a robust research ecosystem and experienced workforce. Health insurance coverage in North America, especially in the United States, plays a pivotal role in making RA drugs accessible to patients. Insurance reimbursement supports patients in accessing these often expensive treatments.

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Rheumatoid Arthritis Drugs players during the forecast period. Factors such as RA prevalence is on the rise in many countries across the Asia-Pacific region, including India and China. This increasing disease burden drives demand for RA drugs. The region is home to a large and rapidly growing population. As the middle class expands and healthcare awareness improves, more people have the financial means and knowledge to seek treatment for RA. Many countries in Asia-Pacific are investing heavily in healthcare infrastructure development. This includes expanding access to quality healthcare services and specialized rheumatology clinics. The pharmaceutical industry in Asia-Pacific is evolving rapidly. Local and multinational pharmaceutical companies are investing in research and development of RA drugs tailored to the region's population.

Key Market Players

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG

Report Scope:

In this report, the Global Rheumatoid Arthritis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rheumatoid Arthritis Drugs Market, By Type of Molecule:

  • Pharmaceuticals
  • Biopharmaceuticals

Rheumatoid Arthritis Drugs Market, By Drug Class:

  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Disease-modifying antirheumatic drugs (DMARDs)
  • Corticosteroids
  • Analgesics
  • Other

Rheumatoid Arthritis Drugs Market, By Distribution Channel:

  • Prescription
  • Over the counter (OTC)

Rheumatoid Arthritis Drugs Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Rheumatoid Arthritis Drugs Market.

Available Customizations:

  • Global Rheumatoid Arthritis Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rheumatoid Arthritis Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type of Molecule (Pharmaceuticals, Biopharmaceuticals)
    • 5.2.2. By Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), Corticosteroids, Analgesics, Other)
    • 5.2.3. By Distribution Channel (Prescription, Over the counter (OTC))
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. North America Rheumatoid Arthritis Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Molecule
    • 6.2.2. By Drug Class
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Rheumatoid Arthritis Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type of Molecule
        • 6.3.1.2.2. By Drug Class
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Rheumatoid Arthritis Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type of Molecule
        • 6.3.2.2.2. By Drug Class
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Rheumatoid Arthritis Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type of Molecule
        • 6.3.3.2.2. By Drug Class
        • 6.3.3.2.3. By Distribution Channel

7. Europe Rheumatoid Arthritis Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Molecule
    • 7.2.2. By Drug Class
    • 7.2.3. By Distribution Channel
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Rheumatoid Arthritis Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type of Molecule
        • 7.3.1.2.2. By Drug Class
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. United Kingdom Rheumatoid Arthritis Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type of Molecule
        • 7.3.2.2.2. By Drug Class
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Italy Rheumatoid Arthritis Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type of Molecule
        • 7.3.3.2.2. By Drug Class
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. France Rheumatoid Arthritis Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type of Molecule
        • 7.3.4.2.2. By Drug Class
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Rheumatoid Arthritis Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type of Molecule
        • 7.3.5.2.2. By Drug Class
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Rheumatoid Arthritis Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Molecule
    • 8.2.2. By Drug Class
    • 8.2.3. By Distribution Channel
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Rheumatoid Arthritis Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type of Molecule
        • 8.3.1.2.2. By Drug Class
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Rheumatoid Arthritis Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type of Molecule
        • 8.3.2.2.2. By Drug Class
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Rheumatoid Arthritis Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type of Molecule
        • 8.3.3.2.2. By Drug Class
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Rheumatoid Arthritis Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type of Molecule
        • 8.3.4.2.2. By Drug Class
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Rheumatoid Arthritis Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type of Molecule
        • 8.3.5.2.2. By Drug Class
        • 8.3.5.2.3. By Distribution Channel

9. South America Rheumatoid Arthritis Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Molecule
    • 9.2.2. By Drug Class
    • 9.2.3. By Distribution Channel
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Rheumatoid Arthritis Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type of Molecule
        • 9.3.1.2.2. By Drug Class
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Rheumatoid Arthritis Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type of Molecule
        • 9.3.2.2.2. By Drug Class
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Rheumatoid Arthritis Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type of Molecule
        • 9.3.3.2.2. By Drug Class
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Rheumatoid Arthritis Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Molecule
    • 10.2.2. By Drug Class
    • 10.2.3. By Distribution Channel
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Rheumatoid Arthritis Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type of Molecule
        • 10.3.1.2.2. By Drug Class
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Rheumatoid Arthritis Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type of Molecule
        • 10.3.2.2.2. By Drug Class
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Rheumatoid Arthritis Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type of Molecule
        • 10.3.3.2.2. By Drug Class
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers & Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Rheumatoid Arthritis Drugs Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. AbbVie Inc.
  • 14.2. Amgen Inc.
  • 14.3. Bayer AG
  • 14.4. Boehringer Ingelheim GmbH
  • 14.5. Bristol-Myers Squibb Company
  • 14.6. Celgene Corporation
  • 14.7. F. Hoffmann-La Roche AG
  • 14.8. Johnson & Johnson
  • 14.9. Merck & Co. Inc.
  • 14.10. Novartis AG

15. Strategic Recommendations

16. About Us & Disclaimer